Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Neoral · 1 trial · 3 indications
| Name | Type | Description |
|---|---|---|
| Neoral | DRUG | - |
| Tacrolimus | DRUG | - |
Inclusion Criteria: * adult patients who have received liver transplant Exclusion Criteria: * pregnant women * nursing women
Neoral is an investigational small molecule being studied for chronic hepatitis C. It was evaluated in a completed Phase 1 trial involving liver transplant recipients with chronic hepatitis C, organ transplantation, and immunosuppression. The drug is still in clinical development and is not approved for this indication.
Neoral is being developed by Novartis AG, a biopharmaceutical company traded on the stock exchange under the ticker symbol NVS. The company conducted a Phase 1 clinical trial of Neoral in patients with chronic hepatitis C.
Neoral is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, uncontrolled study with 40 participants. The drug remains investigational and has not been approved by regulatory authorities for any use.
Neoral has one completed clinical trial registered under NCT00286871, titled 'Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen.' This Phase 1 study enrolled 40 participants in the United States and evaluated Neoral in conditions including chronic hepatitis C, organ transplantation, and immunosuppression.
Neoral is a brand name for cyclosporine, an immunosuppressant drug. In the context of the clinical trial data, Neoral was studied for its effects in liver transplant recipients with chronic hepatitis C. The drug is being developed by Novartis AG.